Our top pick for
Building a portfolio
Nephros, Inc is a medical instruments & supplies business based in the US. Nephros shares (NEPH) are listed on the NASDAQ and all prices are listed in US Dollars. Nephros employs 25 staff and has a trailing 12-month revenue of around USD$9.4 million.
|Latest market close||USD$6.64|
|52-week range||USD$4.42 - USD$10.4018|
|50-day moving average||USD$6.2991|
|200-day moving average||USD$7.1696|
|Wall St. target price||USD$12.92|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.518|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-14.87%|
|1 month (2020-12-22)||-13.32%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||1,006.67%|
|3 years (2018-01-18)||1,283.33%|
|5 years (2016-01-18)||N/A|
|Revenue TTM||USD$9.4 million|
|Gross profit TTM||USD$6.1 million|
|Return on assets TTM||-19.22%|
|Return on equity TTM||-43.07%|
|Market capitalisation||USD$61.6 million|
TTM: trailing 12 months
There are currently 7,139 Nephros shares held short by investors – that's known as Nephros's "short interest". This figure is 65.3% down from 20,563 last month.
There are a few different ways that this level of interest in shorting Nephros shares can be evaluated.
Nephros's "short interest ratio" (SIR) is the quantity of Nephros shares currently shorted divided by the average quantity of Nephros shares traded daily (recently around 6999.0196078431). Nephros's SIR currently stands at 1.02. In other words for every 100,000 Nephros shares traded daily on the market, roughly 1020 shares are currently held short.
However Nephros's short interest can also be evaluated against the total number of Nephros shares, or, against the total number of tradable Nephros shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nephros's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Nephros shares in existence, roughly 0 shares are currently held short) or 0.0012% of the tradable shares (for every 100,000 tradable Nephros shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nephros.
Find out more about how you can short Nephros stock.
We're not expecting Nephros to pay a dividend over the next 12 months.
Nephros's shares were split on a 1:9 basis on 10 July 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nephros shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Nephros shares which in turn could have impacted Nephros's share price.
Over the last 12 months, Nephros's shares have ranged in value from as little as $4.42 up to $10.4018. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nephros's is 0.9144. This would suggest that Nephros's shares are less volatile than average (for this exchange).
Nephros, Inc., a commercial-stage company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to health care, food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.